Effects of kuntai capsule in combination with hormone replacement therapy on premature ovarian failure and bone metabolism.

IF 1 4区医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

African journal of reproductive health Pub Date : 2025-05-30 DOI:10.29063/ajrh2025/v29i5.6

Aidong Shen, Yajun Ren, Jing Ling, Junxu Zhou, Yangyan Sun

{"title":"Effects of kuntai capsule in combination with hormone replacement therapy on premature ovarian failure and bone metabolism.","authors":"Aidong Shen, Yajun Ren, Jing Ling, Junxu Zhou, Yangyan Sun","doi":"10.29063/ajrh2025/v29i5.6","DOIUrl":null,"url":null,"abstract":"<p><p>This study evaluates the clinical effectiveness of combining kuntai capsule with hormone replacement therapy (HRT) in treating premature ovarian failure (POF) and its impact on ovarian reserve and bone metabolism. A total of 190 POF patients were randomly assigned to either a control group (n=95) receiving HRT alone (1 mg estradiol valerate tablets and 10 mg dydrogesterone tablets), or an observation group (n=95) receiving a combination of HRT and Kuntai Capsule. After three months of treatment, the observation group showed significantly better ovarian reserve, with a higher overall effective rate (87.37% vs. 71.58%). Hormonal analysis revealed lower follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, and higher estradiol (E2) levels in the observation group compared to the control. Furthermore, ovarian reserve markers such as anti-Müllerian hormone (AMH) and antral follicle count were also higher in the observation group. Bone metabolism improvements were noted, with higher osteocalcin (OST) and lower bone-specific alkaline phosphatase (BAP) levels. The observation group also had a significantly lower recurrence rate (7.3%) after 24 months, compared to the control group (16.8%). These results suggest that the combination of Kuntai Capsule and HRT offers a promising treatment for POF, improving ovarian function, hormone levels, and bone health while reducing recurrence risk.</p>","PeriodicalId":7551,"journal":{"name":"African journal of reproductive health","volume":"29 5","pages":"63-73"},"PeriodicalIF":1.0000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African journal of reproductive health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.29063/ajrh2025/v29i5.6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

This study evaluates the clinical effectiveness of combining kuntai capsule with hormone replacement therapy (HRT) in treating premature ovarian failure (POF) and its impact on ovarian reserve and bone metabolism. A total of 190 POF patients were randomly assigned to either a control group (n=95) receiving HRT alone (1 mg estradiol valerate tablets and 10 mg dydrogesterone tablets), or an observation group (n=95) receiving a combination of HRT and Kuntai Capsule. After three months of treatment, the observation group showed significantly better ovarian reserve, with a higher overall effective rate (87.37% vs. 71.58%). Hormonal analysis revealed lower follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, and higher estradiol (E2) levels in the observation group compared to the control. Furthermore, ovarian reserve markers such as anti-Müllerian hormone (AMH) and antral follicle count were also higher in the observation group. Bone metabolism improvements were noted, with higher osteocalcin (OST) and lower bone-specific alkaline phosphatase (BAP) levels. The observation group also had a significantly lower recurrence rate (7.3%) after 24 months, compared to the control group (16.8%). These results suggest that the combination of Kuntai Capsule and HRT offers a promising treatment for POF, improving ovarian function, hormone levels, and bone health while reducing recurrence risk.

查看原文本刊更多论文

坤泰胶囊联合激素替代疗法对卵巢早衰及骨代谢的影响。

本研究评价坤泰胶囊联合激素替代疗法（HRT）治疗卵巢早衰（POF）的临床疗效及对卵巢储备和骨代谢的影响。190例POF患者随机分为对照组（95例）单独接受HRT治疗（戊酸雌二醇片1 mg和地屈孕酮片10 mg）和观察组（95例）联合接受HRT和坤泰胶囊治疗。治疗3个月后，观察组卵巢储备功能明显改善，总有效率更高（87.37% vs. 71.58%）。激素分析显示，与对照组相比，观察组的促卵泡激素（FSH）和黄体生成素（LH）水平较低，雌二醇（E2）水平较高。观察组抗勒氏激素（AMH）、窦卵泡计数等卵巢储备指标均高于对照组。骨代谢得到改善，骨钙素（OST）升高，骨特异性碱性磷酸酶（BAP）水平降低。观察组24个月后复发率（7.3%）明显低于对照组（16.8%）。这些结果表明，坤泰胶囊联合HRT治疗POF是一种很有前景的治疗方法，可以改善卵巢功能、激素水平和骨骼健康，同时降低复发风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

African journal of reproductive health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

1.20

自引率

10.00%

发文量

期刊介绍： The African Journal of Reproductive Health is a multidisciplinary and international journal that publishes original research, comprehensive review articles, short reports, and commentaries on reproductive heath in Africa. The journal strives to provide a forum for African authors, as well as others working in Africa, to share findings on all aspects of reproductive health, and to disseminate innovative, relevant and useful information on reproductive health throughout the continent.